Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Form 4 Overview – Amphastar Pharmaceuticals, Inc. (AMPH)
Director Floyd F. Petersen disclosed the sale of 500 shares of Amphastar Pharmaceuticals common stock on 07 July 2025 (trade date 07/02/2025) at a weighted-average price of $23.4679 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 26 November 2024. Following the sale, Petersen’s direct ownership stands at 77,531 shares.
No derivative securities were involved and no other transactions were reported.
- Percentage of holdings sold: roughly 0.6 % of the director’s reported stake.
- The filing indicates continued direct ownership; no change to indirect holdings was reported.
- Rule 10b5-1 plan suggests the trade was scheduled in advance, reducing concerns over information asymmetry.
Given the modest size of the sale relative to total ownership and the use of a 10b5-1 plan, the market impact is likely limited.